Search clinical trials for: brinzolamide 1% ophthalmic suspension

Total 300 results

Alcon Research

Completed

6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma
Actavis Inc.

Completed

Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes

Glaucoma

United States
Padagis LLC

Completed

To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes

Ocular Hypertension | Glaucoma, Open-Angle

United States
Bausch & Lomb Incorporated

Completed

Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt

Glaucoma | Open Angle or Ocular Hypertension

United States
Bausch & Lomb Incorporated

Completed

Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt

Glaucoma | Open Angle or Ocular Hypertension

United States
Alcon Research

Completed

Fixed Combination Brinzolamide 1%/Timolol 0.5% Versus Brinzolamide 1% + Timolol 0.5% in Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma
Alcon Research

Completed

Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma
Alcon Research

Completed

Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%

Ocular Hypertension | Open-Angle Glaucoma
Alcon Research

Completed

A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2%

Ocular Hypertension | Open-Angle Glaucoma
Alcon Research

Terminated

Safety and Efficacy of Brinzolamide/Brimonidine Fixed Combination

Ocular Hypertension | Open-Angle Glaucoma
Alcon Research

Completed

Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma
Alcon Research

Completed

Efficacy and Safety Study of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2%

Ocular Hypertension | Open-Angle Glaucoma
Padagis LLC

Completed

To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes

Ocular Hypertension | Glaucoma, Open-Angle

United States
Reata, a wholly owned subsidiary of Biogen
AbbVie

Completed

RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD

Ocular Inflammation | Ocular Pain | Corneal Endothelial Cell Loss | Cataract Surgery

United States
Sun Pharmaceutical Industries Limited

Completed

A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Primary Open Angle Glaucoma | Ocular Hypertension

India, Russian Federation
Reata, a wholly owned subsidiary of Biogen
AbbVie

Completed

RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery

Inflammation and Pain Following Ocular Surgery

United States
Bausch & Lomb Incorporated

Completed

Study to Assess the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome

Dry Eye Syndrome

United States
Alcon Research

Completed

A Comparison of Azopt Versus Placebo Added to Xalatan in Patients With Elevated Intraocular Pressure (IOP) on a Prostaglandin

Glaucoma

United States
Alcon Research

Completed

SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)

Ocular Hypertension | Open-Angle Glaucoma

United States
Alcon, a Novartis Company

Completed

Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution

Ocular Hypertension | Open-Angle Glaucoma

Japan
Santen Inc.

Completed

Study Assessing Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients

Dry Eye

United States
Santen Inc.

Completed

A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients

Dry Eye Disease

United States
General Hospital of Athens Elpis

Completed

Brinzolamide-brimonidine Fixed Combination for Preventing IOP Elevation After Intravitreal Anti-VEGF Injections

Eye Diseases | Intraocular Pressure | Injection Complication

Greece
Alcon Research

Terminated

Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®

Ocular Hypertension | Open-angle Glaucoma

United States
Alcon Research

Completed

Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®

Ocular Hypertension | Open Angle Glaucoma
Alcon Research

Completed

Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue

Ocular Hypertension | Open Angle Glaucoma
University Hospital of Patras

Completed

Effect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After Phacoemulsification

Cataract | Intraocular Pressure

Greece
Akron Children's Hospital

Completed

Topical Brinzolamide Ophthalmic Suspension Versus Placebo in the Treatment of Infantile Nystagmus Syndrome

Infantile Nystagmus Syndrome

United States
Alcon Research

Completed

24-hr Intraocular Pressure Control With SIMBRINZA ®

Glaucoma
Tel-Aviv Sourasky Medical Center

Unknown

Brinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy

Central Serous Chorioretinopathy

Israel, Argentina
Adapt Produtos Oftalmológicos Ltda.

Withdrawn

Latanoprost/Brinzolamide BID Versus Latanoprost BID in Patients With OAG or OH

Ocular Hypertension | Open Angle Glaucoma

Brazil
Santen Inc.
ActualEyes Inc.

Active, not recruiting

A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD) (PHANTOM)

Fuchs Endothelial Corneal Dystrophy

United States, France, India
Santen Inc.

Completed

Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye Disease

Dry Eye

United States
Alcon Research

Completed

Patient Preference Comparison of AZARGA Versus COSOPT

Ocular Hypertension | Open-Angle Glaucoma
Alcon Research

Completed

Safety and Intraocular Pressure (IOP)-Lowering Efficacy of AL-39256 in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma
Alcon Research

Completed

A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma

United States
Kala Pharmaceuticals, Inc.

Completed

Safety and Efficacy of KPI-121 in Subjects With DED (STRIDE 3)

Kerato Conjunctivitis Sicca

United States
Kala Pharmaceuticals, Inc.

Completed

Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain

Post Surgical Ocular Inflammation and Pain

United States
Betaliq, Inc.
Trial Runners, LLC; Summit Analytical, LLC

Completed

Nebivolol 0.5, 1.0, or Timolol 0.5 Suspension Compared to Timolol 0.5 Solution to Treat Glaucoma/Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

United States
Alcon Research

Completed

Efficacy and Safety of Brinzolamide/Brimonidine Fixed Combination BID Compared to Brinzolamide BID Plus Brimonidine BID in Subjects With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)

Ocular Hypertension | Open-Angle Glaucoma
Hanlim Pharm. Co., Ltd.

Completed

A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of HL217 Eye Drop in Healthy Male Subjects

Healthy Subject
Otsuka Pharmaceutical Co., Ltd.

Completed

Late Phase 2 Study of OPC-12759 Ophthalmic Suspension

Dry Eye Syndromes

Japan
Novartis Pharmaceuticals

Completed

Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma

Glaucoma

Korea, Republic of
Guangzhou HuiBoRui Biological Pharmaceutical Technology...
Parexel

Unknown

Clinical Evaluation of Safety and Tolerability of KDR2-2 Eye Drops in Healthy Volunteers With Pharmacokinetic Assessment

Corneal Neovascularization

United States
Kala Pharmaceuticals, Inc.

Completed

Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation (Hawaii-1)

Ocular Infections, Irritations and Inflammations

United States
Kala Pharmaceuticals, Inc.

Completed

Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease (STRIDE 2)

Dry Eye Syndromes | Keratoconjunctivitis Sicca

United States
Kala Pharmaceuticals, Inc.

Completed

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease (STRIDE 1)

Dry Eye Syndromes | Keratoconjunctivitis Sicca

United States
Kala Pharmaceuticals, Inc.

Completed

Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema (Molokini)

Diabetic Macular Edema | Retinal Vein Occlusion

United States
PanOptica, Inc.

Completed

Study of PAN-90806 Eye Drops, Suspension for Neovascular AMD

Neovascular Age-related Macular Degeneration

United States, Czechia, United Kingdom, Hungary, Latvia
Kala Pharmaceuticals, Inc.

Completed

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease (Kauai)

Dry Eye Syndromes | Keratoconjunctivitis Sicca

United States

3

Subscribe